Estimulação Cerebral Profunda no Tratamento da Doença de Parkinson: Revisão de Literatura / Deep Brain Stimulation in the Treatment of Parkinson's Disease: Literature Review

A doença de Parkinson é considerada um distúrbio neurológico do sistema nervoso central, possuindo um caráter crônico e progressivo. A estimulação cerebral profunda (ECP), é um procedimento cirúrgico pouco invasivo, atualmente, muito utilizado na doença de Parkinson como uma alternativa terapêutica eficaz e segura, com melhora expressiva na sintomatologia da doença. A ECP é realizada através da colocação de elétrodos em regiões profundas do cérebro de modo a que a estimulação elétrica alcance estás regiões.  Está, tem demonstrado um aumento significativo na flexibilidade cognitiva e na otimização do tratamento em casos severos

Gastrite cística profunda: revisão integrativa acerca de um acometimento raro / Deep cystic gastritis: integrative review about a rare event

A Gastrite Cística Profunda (GCP) é uma condição rara, caracterizada por uma lesão hiperplásica benigna polipóide, em que há uma dilatação cística e migração de células epiteliais para a camada submucosa. Sua etiologia ainda não é bem definida, mas as causas mais significativas, provavelmente sejam cirurgia gástrica prévia e lesão da parede gástrica, tradicionalmente em pacientes que já realizaram gastroenterostomia, tendo predomínio em idosos com cerca de 60 anos, apesar de poder ocorrer em jovens. O objetivo dessa revisão é reunir literaturas disponíveis mais recentes a fim de ampliar o conhecimento sobre esta patologia considerada rara, facilitando o raciocínio clínico e o diagnóstico diferencial. Foram utilizados 25 artigos encontrados na PubMed a partir dos descritores “deep polyposis cystic gastritis”, “deep cystic gastritis” “rare diseases” e “benign”, com critério de exclusão para artigos que não possuíam texto completo gratuito e anteriores a 2010. Conclui-se que a gastrite cística profunda é uma patologia pouco descrita, e mesmo com procura ativa de artigos, observa-se escassez de informações, sem conclusões efetivas em relação à patogenia, epidemiologia e tratamento, evidenciando ainda a presença de sintomas inespecíficos, definida como uma doença incomum

Linfoma de burkitt como causa de pancreatite aguda: revisão bibliográfica/ Burkitt lyphoma as a cause of acute pancreatitis: bibliographic review

O Linfoma de Burkitt (LB), pertencente à família dos Linfomas Não-Hodgkin, de células B, é altamente agressivo. Sua etiologia está intimamente relacionada a doenças infecciosas e desregulação imune. Os sinais clínicos implicam em perda de peso, anorexia, dor abdominal, diarreia, icterícia de padrão obstrutivo, anemia, plaquetopenia e presença de massa abdominal quando ali originado, a qual, dependendo do tipo de manifestação clínica, pode levar a uma invasão do pâncreas, ocasionando pancreatite aguda. Assim, há necessidade de análise dos fatores predisponentes do Linfoma de Burkitt como causa de pancreatite aguda, visando elucidação médica acerca da sua etiopatogenia, perfil epidemiológico e manifestações clínicas. As informações aqui expostas, foram levantadas utilizando a base de dados do Medline/Pubmed e The Scientific Electronic Library Online - SciELO. O LB com envolvimento pancreático é prevalente em idades jovens. Nos casos de idade avançada, a injúria do pâncreas é rara e denota uma doença pré-terminal. O tipo endêmico acomete principalmente os afrodescendentes e o esporádico a raça caucasiana. O exame de imagem padrão ouro para avaliar neoplasias com envolvimento do pâncreas é a Ressonância Magnética, pertinente pela boa visualização do comprometimento de vasos pancreáticos e linfonodos adjacentes. Biomarcadores tumorais típicos, como BCL-6 e CD10, podem ser requisitados nos casos suspeitos e indefinidos. Os níveis séricos de amilase e lipase são bons indicadores de um processo danoso do tecido pancreático. De acordo com os dados da evolução de pacientes pediátricos com LB, a resposta à quimioterapia, sozinha, é excelente, no que difere muito de outras neoplasias de crescimento acelerado. Mas isso depende fundamentalmente de um diagnóstico precoce. O estudo e divulgação dessa apresentação, apesar de incomum, contribui para melhor acurácia no diagnóstico e manejo da conduta clínica

Statistical experimental design to assess the influence of enzymes of nematophagous fungi versus helminths

The present work used Plackett–Burman experimental design to assess the influence of enzymes of nematophagous fungi versus Strongyloides westeri and trichostrongylides larvae and Platynosomum fastosum eggs. The variables studied in the Plackett–Burman design were the proteases and chitinases of AC001 or VC4 as destructive agents of S. westeri and trichostrongylides larvae, and P. fastosum eggs. All tested enzymes had a significant effect (P < 0.05) on the destruction of S. westeri larvae. Furthermore, only VC4 and AC001 proteases showed a significant effect (P < 0.05) on the destruction of trichostrongylides larvae. On the other hand, chitinases of VC4 showed the highest significance (P < 0.05) on the destruction of P. fastosum eggs. It is proposed that statistical planning for the use of enzymes derived from nematophagous fungi is a viable way to elucidate some questions about their mechanism of action

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

BackgroundEstimates of demographic metrics are crucial to assess levels and trends of population health outcomes. The profound impact of the COVID-19 pandemic on populations worldwide has underscored the need for timely estimates to understand this unprecedented event within the context of long-term population health trends. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides new demographic estimates for 204 countries and territories and 811 additional subnational locations from 1950 to 2021, with a particular emphasis on changes in mortality and life expectancy that occurred during the 2020–21 COVID-19 pandemic period.Methods22 223 data sources from vital registration, sample registration, surveys, censuses, and other sources were used to estimate mortality, with a subset of these sources used exclusively to estimate excess mortality due to the COVID-19 pandemic. 2026 data sources were used for population estimation. Additional sources were used to estimate migration; the effects of the HIV epidemic; and demographic discontinuities due to conflicts, famines, natural disasters, and pandemics, which are used as inputs for estimating mortality and population. Spatiotemporal Gaussian process regression (ST-GPR) was used to generate under-5 mortality rates, which synthesised 30 763 location-years of vital registration and sample registration data, 1365 surveys and censuses, and 80 other sources. ST-GPR was also used to estimate adult mortality (between ages 15 and 59 years) based on information from 31 642 location-years of vital registration and sample registration data, 355 surveys and censuses, and 24 other sources. Estimates of child and adult mortality rates were then used to generate life tables with a relational model life table system. For countries with large HIV epidemics, life tables were adjusted using independent estimates of HIV-specific mortality generated via an epidemiological analysis of HIV prevalence surveys, antenatal clinic serosurveillance, and other data sources. Excess mortality due to the COVID-19 pandemic in 2020 and 2021 was determined by subtracting observed all-cause mortality (adjusted for late registration and mortality anomalies) from the mortality expected in the absence of the pandemic. Expected mortality was calculated based on historical trends using an ensemble of models. In location-years where all-cause mortality data were unavailable, we estimated excess mortality rates using a regression model with covariates pertaining to the pandemic. Population size was computed using a Bayesian hierarchical cohort component model. Life expectancy was calculated using age-specific mortality rates and standard demographic methods. Uncertainty intervals (UIs) were calculated for every metric using the 25th and 975th ordered values from a 1000-draw posterior distribution.FindingsGlobal all-cause mortality followed two distinct patterns over the study period: age-standardised mortality rates declined between 1950 and 2019 (a 62·8% [95% UI 60·5–65·1] decline), and increased during the COVID-19 pandemic period (2020–21; 5·1% [0·9–9·6] increase). In contrast with the overall reverse in mortality trends during the pandemic period, child mortality continued to decline, with 4·66 million (3·98–5·50) global deaths in children younger than 5 years in 2021 compared with 5·21 million (4·50–6·01) in 2019. An estimated 131 million (126–137) people died globally from all causes in 2020 and 2021 combined, of which 15·9 million (14·7–17·2) were due to the COVID-19 pandemic (measured by excess mortality, which includes deaths directly due to SARS-CoV-2 infection and those indirectly due to other social, economic, or behavioural changes associated with the pandemic). Excess mortality rates exceeded 150 deaths per 100 000 population during at least one year of the pandemic in 80 countries and territories, whereas 20 nations had a negative excess mortality rate in 2020 or 2021, indicating that all-cause mortality in these countries was lower during the pandemic than expected based on historical trends. Between 1950 and 2021, global life expectancy at birth increased by 22·7 years (20·8–24·8), from 49·0 years (46·7–51·3) to 71·7 years (70·9–72·5). Global life expectancy at birth declined by 1·6 years (1·0–2·2) between 2019 and 2021, reversing historical trends. An increase in life expectancy was only observed in 32 (15·7%) of 204 countries and territories between 2019 and 2021. The global population reached 7·89 billion (7·67–8·13) people in 2021, by which time 56 of 204 countries and territories had peaked and subsequently populations have declined. The largest proportion of population growth between 2020 and 2021 was in sub-Saharan Africa (39·5% [28·4–52·7]) and south Asia (26·3% [9·0–44·7]). From 2000 to 2021, the ratio of the population aged 65 years and older to the population aged younger than 15 years increased in 188 (92·2%) of 204 nations.InterpretationGlobal adult mortality rates markedly increased during the COVID-19 pandemic in 2020 and 2021, reversing past decreasing trends, while child mortality rates continued to decline, albeit more slowly than in earlier years. Although COVID-19 had a substantial impact on many demographic indicators during the first 2 years of the pandemic, overall global health progress over the 72 years evaluated has been profound, with considerable improvements in mortality and life expectancy. Additionally, we observed a deceleration of global population growth since 2017, despite steady or increasing growth in lower-income countries, combined with a continued global shift of population age structures towards older ages. These demographic changes will likely present future challenges to health systems, economies, and societies. The comprehensive demographic estimates reported here will enable researchers, policy makers, health practitioners, and other key stakeholders to better understand and address the profound changes that have occurred in the global health landscape following the first 2 years of the COVID-19 pandemic, and longer-term trends beyond the pandemic